The 31st N.A. Semashko Russian Pharmaceutical Forum was held in Saint Petersburg on May 14-15, 2024 with the support of the FSI “SID&GP” of the Ministry of Industry and Trade of Russia

 
On the first day of the Forum, as part of the business program, there was held a plenary session, an open dialogue, between the representatives of regulatory authorities, professional associations, scientific organizations and pharmaceutical industry experts. The plenary session was attended by the representatives of the Ministry of Health of the Russian Federation, the Ministry of Industry and Trade of the Russian Federation, the Federal Antimonopoly Service, the Association of International Pharmaceutical Manufacturers, the Union of Professional Pharmaceutical Organizations, the N.A. Semashko National Research Institute of Public Health.

A large-scale plenary session “Affordable and Effective Healthcare System” was held on the first day of the forum. During the first part of the plenary session, CEOs of large pharma companies exchanged views on the priorities of pharma industry development in new reality, spoke about their best practices, and discussed issues on how to ensure the sustainability in the pharma market and drugs availability.

Vladislav Shestakov, Director of the FSI “State Institute of Drugs and Good Practices” (“SID&GP”) of the Ministry of Industry and Trade of Russia moderated the second part of the plenary session “Government Agencies on the Implementation of Government Support Measures for the Pharmaceutical Industry.”

In addition, Vladislav Shestakov participated in the session “Commercial Segment. Production and Availability of OTC Drugs and Dietary Supplements for Consumers,” during which he emphasized the importance of compliance of the manufacturers of dietary supplements with the quality control standards. Nowadays, the manufacturers of dietary supplements often tend to submit a HACCP (Hazard Analysis and Critical Control Points) certificate, which, however, does not include the specific requirements for production, rather than a GMP certificate.

Razia Solodova, Head of the Center for Industry Analytics of “SID&GP”, Ministry of Industry and Trade of the Russian Federation, took part in the analytical session “Global and Local Pharmaceutical Trends and Forecasts”, dedicated to the analysis of the status of the pharmaceutical industry. In her report she stated that the sharp increase in export volumes of vaccines produced in Russia, which occurred in 2021, and was caused by the pandemic, clearly showed the demand for the Russian innovative products by the global pharma community.

According to the expert, currently, the Russian manufacturers have great potential to export medicinal products. An innovative drug for treatment of ankylosing spondylitis, developed by company Biocad, was mentioned as an example. At the same time, within the framework of Strategy 2030, measures have been identified to support the export of medicinal products from the Russian Federation and work is underway in that direction.